The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
Open accessAbstract
The identification of the molecular events that drive cancer transformation is essential to the development of targeted agents that improve the clinical outcome of lung cancer. Many studies have reported genomic driver mutations in non-small-cell lung cancers (NSCLCs) over the past decade; however, the molecular pathogenesis of >40% of NSCLCs is still unknown. To identify new molecular targets in NSCLCs, we performed the combined analysis of massively parallel whole-genome and transcriptome sequencing for cancer and paired normal tissue of a 33-yr-old lung adenocarcinoma patient, who is a never-smoker and has no familial cancer history. The cancer showed no known driver mutation in EGFR or KRAS and no EML4-ALK fusion. Here we report a novel fusion gene between KIF5B and the RET proto-oncogene caused by a pericentric inversion of 10p11.22–q11.21. This fusion gene overexpresses chimeric RET receptor tyrosine kinase, which could spontaneously induce cellular transformation. We identified the KIF5B-RET fusion in two more cases out of 20 primary lung adenocarcinomas in the replication study. Our data demonstrate that a subset of NSCLCs could be caused by a fusion of KIF5B and RET, and suggest the chimeric oncogene as a promising molecular target for the personalized diagnosis and treatment of lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
A map of human genome variation from population-scale sequencing.
The 1000 Genomes Project Consortium (2010) · Nature · doi:10.1038/nature09534 · Cited by 7,877
Kumar, P., Henikoff, S., & Ng, P. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.86 · Cited by 6,521
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Protein structure prediction on the Web: a case study using the Phyre server
Kelley, L. A., & Sternberg, M. J. E. (2009) · Nature Protocols · doi:10.1038/nprot.2009.2 · Cited by 4,175
Cited by
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
Mechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
Understanding and targeting resistance mechanisms in NSCLC
Rotow, J., & Bivona, T. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.84 · Cited by 972
Dearden, S., Stevens, J., Wu, Y.-L., & Blowers, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt205 · Cited by 646
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Vaishnavi, A., Le, A. T., & Doebele, R. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0765 · Cited by 642
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Vaishnavi, A., Capelletti, M., Le, A. T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K. D., Aisner, D. L., Pilling, A. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3352 · Cited by 607
Self-citationA survey of tools for variant analysis of next-generation genome sequencing data
Pabinger, S., Dander, A., Fischer, M., Snajder, R., Sperk, M., Efremova, M., Krabichler, B., Speicher, M. R., Zschocke, J., & Trajanoski, Z. (2014) · Briefings in Bioinformatics · doi:10.1093/bib/bbs086 · Cited by 596
The transcriptional landscape and mutational profile of lung adenocarcinoma
Seo, J.-S., Ju, Y. S., Lee, W.-C., Shin, J.-Y., Lee, J. K., Bleazard, T., Lee, J., Jung, Y. J., Kim, J.-O., Shin, J.-Y., et al. (2012) · Genome Research · doi:10.1101/gr.145144.112 · Cited by 584
Self-citationRET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
Wang, R., Hu, H., Pan, Y., Li, Y., Ye, T., Li, C., Luo, X., Wang, L., Li, H., Zhang, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1477 · Cited by 546
Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression
Selamat, S. A., Chung, B. S., Girard, L., Zhang, W., Zhang, Y., Campan, M., Siegmund, K. D., Koss, M. N., Hagen, J. A., Lam, W. L., et al. (2012) · Genome Research · doi:10.1101/gr.132662.111 · Cited by 521
A Genomics-Based Classification of Human Lung Tumors
The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM) (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 511
Drilon, A., Rekhtman, N., Arcila, M., Wang, L., Ni, A., Albano, M., Van Voorthuysen, M., Somwar, R., Smith, R. S., Montecalvo, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30562-9 · Cited by 484
Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
Drilon, A., Wang, L., Hasanovic, A., Suehara, Y., Lipson, D., Stephens, P., Ross, J., Miller, V., Ginsberg, M., Zakowski, M. F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0035 · Cited by 464
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.001 · Cited by 462
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2012-0720-oa · Cited by 426
Kobayashi, Y., & Mitsudomi, T. (2016) · Cancer Science · doi:10.1111/cas.12996 · Cited by 413
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
Subbiah, V., Gainor, J. F., Rahal, R., Brubaker, J. D., Kim, J. L., Maynard, M., Hu, W., Cao, Q., Sheets, M. P., Wilson, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0338 · Cited by 396
Self-citationGenetic alterations defining NSCLC subtypes and their therapeutic implications
Pikor, L. A., Ramnarine, V. R., Lam, S., & Lam, W. L. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.025 · Cited by 375
Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
Gainor, J. F., & Shaw, A. T. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0095 · Cited by 342
Refining the treatment of NSCLC according to histological and molecular subtypes
Thomas, A., Liu, S. V., Subramaniam, D. S., & Giaccone, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.90 · Cited by 321
Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations
Li, Y. Y., Chung, G. T. Y., Lui, V. W. Y., To, K.-F., Ma, B. B. Y., Chow, C., Woo, J. K., Yip, K. Y., Seo, J., Hui, E. P., et al. (2017) · Nature Communications · doi:10.1038/ncomms14121 · Cited by 309
Self-citationTargeted genomic rearrangements using CRISPR/Cas technology
Choi, P. S., & Meyerson, M. (2014) · Nature Communications · doi:10.1038/ncomms4728 · Cited by 309
Molecular biology of lung cancer.
Cooper, W. A., Lam, D. C.-L., O'Toole, S. A., & Minna, J. D. (2013) · PubMed · doi:10.3978/j.issn.2072-1439.2013.08.03 · Cited by 303
New Targetable Oncogenes in Non–Small-Cell Lung Cancer
Oxnard, G. R., Binder, A., & Jänne, P. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.9829 · Cited by 299
Yoh, K., Seto, T., Satouchi, M., Nishio, M., Yamamoto, N., Murakami, H., Nogami, N., Matsumoto, S., Kohno, T., Tsuta, K., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30322-8 · Cited by 294
Tyrosine kinase gene rearrangements in epithelial malignancies
Shaw, A. T., Hsu, P. P., Awad, M. M., & Engelman, J. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3612 · Cited by 292
Okamoto, K., Kodama, K., Takase, K., Sugi, N. H., Yamamoto, Y., Iwata, M., & Tsuruoka, A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.007 · Cited by 288
Diagnosis and Molecular Classification of Lung Cancer
Rodriguez-Canales, J., Parra-Cuentas, E., & Wistuba, I. I. (2016) · Cancer Treatment and Research · doi:10.1007/978-3-319-40389-2_2 · Cited by 273
Yoo, S.-K., Song, Y. S., Lee, E. K., Hwang, J., Kim, H. H., Jung, G., Kim, Y. A., Kim, S.-J., Cho, S. W., Won, J.-K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10680-5 · Cited by 268
Self-citationBeyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Kohno, T., Nakaoku, T., Tsuta, K., Tsuchihara, K., Matsumoto, S., Yoh, K., & Goto, K. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2014.11.11 · Cited by 263
State-of-the-Art Strategies for Targeting RET-Dependent Cancers
Subbiah, V., Yang, D., Velcheti, V., Drilon, A., & Meric-Bernstam, F. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02551 · Cited by 258
Li, A. Y., McCusker, M. G., Russo, A., Scilla, K. A., Gittens, A., Arensmeyer, K., Mehra, R., Adamo, V., & Rolfo, C. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101911 · Cited by 257
Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma
Lee, J. J.-K., Park, S., Park, H., Kim, S., Lee, J., Lee, J., Youk, J., Yi, K., An, Y., Park, I. K., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.013 · Cited by 233
Self-citationLopez-Chavez, A., Thomas, A., Rajan, A., Raffeld, M., Morrow, B., Kelly, R., Carter, C. A., Guha, U., Killian, K., Lau, C. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.2007 · Cited by 233
Molecular pathways and therapeutic targets in lung cancer
Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1891 · Cited by 220
“The most common fusion partner of RET in NSCLC is KIF5B, a gene in the family of motor proteins, kinesins [117, 123, 124].”
BackgroundFluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity
Yu, Y., Liu, A., Dhawan, G., Mei, H., Zhang, W., Izawa, K., Soloshonok, V. A., & Han, J. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.05.042 · Cited by 182
Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation
Gong, M., Li, Y., Ye, X., Zhang, L., Wang, Z., Xu, X., Shen, Y., & Zheng, C. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00568-z · Cited by 86
Identification and Characterization of Oncogenic SOS1 Mutations in Lung Adenocarcinoma
Cai, D., Choi, P. S., Gelbard, M., & Meyerson, M. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0316 · Cited by 41
Identifying common transcriptome signatures of cancer by interpreting deep learning models
Jha, A., Quesnel-Vallières, M., Wang, D., Thomas-Tikhonenko, A., Lynch, K. W., & Barash, Y. (2022) · Genome Biology · doi:10.1186/s13059-022-02681-3 · Cited by 39
Metadata
- Authors
- Ju, Y. S., Lee, W.-C., Shin, J.-Y., Lee, S., Bleazard, T., Won, J.-K., Kim, Y. T., Kim, J.-I., Kang, J.-H., & Seo, J.-S.
- Venue
- Genome Research
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2011-12-22
- Volume
- 22
- Issue
- 3
- Pages
- 436-445
- ISSN
- 1088-9051 (ISSN-L)
- OpenAlex
- W2122133689
- Cited by
- 484
- References
- 40
- Type
- posted content
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.